Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/3031087-thalassemia-pipeline-review-h1-2018
Major Key Players:
Agios Pharmaceuticals Inc
bluebird bio Inc
Cadila Healthcare Ltd
Editas Medicine Inc
- Hoffmann-La Roche Ltd
Gamida Cell Ltd
Thalassemia Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Thalassemia , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 7, 5, 3, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 3 and 1 molecules, respectively.
Thalassemia pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Thalassemia - Competitive Analysis
Key players are making innovative developments in Thalassemia industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia.
The pipeline guide reviews pipeline therapeutics for Thalassemia by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Thalassemia therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Thalassemia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia.
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3031087-thalassemia-pipeline-review-h1-2018
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)